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Abstract
Background: The aim of this study was to evaluate the predictive value of cystatin C (CysC) and estimated
glomerular filtration rate (eGFR) regarding vascular lesions and their severity in patients with acute coronary
syndrome (ACS).
Methods: According to the results of coronary angiography, 195 ACS patients were divided into a single-vascular-
lesion group (91 cases), a dual-vascular-lesion group (67 cases), and a multiple-vascular-lesion group (37 cases) to
assess the severity of coronary artery disease according to Gensini scores and to analyze the correlations of CysC
and eGFR level with vascular lesions and severity in ACS patients.
Results: Intergroup comparisons of univariate and multivariate regression analyses showed that CysC was positively
correlated with vascular lesions (P < 0.05), but eGFR showed no correlation. Regarding the severity of vascular
lesions, CysC was positively correlated with Gensini score (Pearson’s correlation coefficient r = 0.1811, P < 0.05),
but eGFR was not correlated (P > 0.05).
Conclusions: Serum CysC levels could reflect the severity of vascular lesions in ACS patients, and a high CysC
level had predictive value regarding the severity of vascular lesions in ACS.
Keywords: Acute coronary syndrome, Serum cystatin C, Glomerular filtration rate, Correlation study
Background
With changes in lifestyles and diet structures in China,
current heart disease spectra have changed, and coron-
ary heart disease (CHD) has become the most common
cardiac disease. Meanwhile, with the acceleration of the
aging process, the morbidity and mortality of CHD are
exhibiting a rapidly increasing trend, and it has become
a major chronic noncommunicable disease severely
harming public health. Acute coronary syndrome (ACS),
characterized by high incidence, high mortality, and high
recurrence, is currently one of the diseases that is a ser-
ious hazard to human health. ACS includes ST segment-
elevated myocardial infarction (STEMI), non-ST
segment-elevated myocardial infarction (NSTEMI), and
unstable angina. Different forms of ACS share a com-
mon pathophysiological basis, namely coronary
atherosclerosis-based atheromatous plaque loosening,
cracks, or rupture, so the intra-plaque substances that
might result in thrombosis would be exposed in the
blood, causing adhesion, activation, and aggregation of
platelets on the damaged surface, followed by throm-
bosis as well as complete or incomplete occlusion of the
diseased vessels. Cystatin C (CysC) and glomerular filtra-
tion rate (GFR) are indicators that could reflect renal
dysfunction; the former is one of the sensitive indexes
used to evaluate GFR [1] and could detect early renal
damage. The important function of CysC is to regulate
the hydrolysis of cysteine proteases; by inhibiting the ac-
tivity of endogenous cysteine proteases, cell damage can
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be avoided. Recent studies showed that CysC partici-
pates in inflammatory reactions, production of vascular
wall matrix, and homeostasis of degradation as well as
the pathological processes of vascular injuries; it might
also participate in regulating the formation, stabilization,
and regression of atherosclerotic plaques [2]. Therefore,
it would have predictive value regarding the prognosis of
coronary artery disease (CAD) [3–5]. Meanwhile, CysC
also exhibited predictive value regarding the morbidity
and mortality of cardiovascular disease in people with
normal renal function [6–8]. GFR equations based on
CysC or a combination of CysC with creatinine may be
superior to GFR equations based on creatinine alone in
patients with CAD [9]. However, because the correla-
tions of these two factors with ACS are rare, further
study is still needed to determine whether CysC could
be used to predict the severity of vascular disease. A
number of studies about the correlations of CysC and
CHD reported inconsistent conclusions. Therefore, this
study aimed to further clarify the correlations of these




Inclusion criteria: A total of 195 patients with ACS diag-
nosed and hospitalized in our hospital from July 2012 to
June 2013 were enrolled. All the patients met the diag-
nostic criteria of ACS defined by the ACC/AHA in 2014
[10] and were confirmed by coronary angiography
(CAG) to have stenosis ≥50% in at least one coronary
artery. Another 39 patients with negative CAG results
were selected during the same period for a total enroll-
ment of 234 patients. This study was conducted in
accordance with the declaration of Helsinki. This study
was conducted with approval from the Ethics Commit-
tee of the North Huashan Hospital. Written informed
consent was obtained from all participants.
Exclusion criteria: Patients were excluded if they had
severe liver dysfunction (combined with jaundice, portal
hypertension, ascites, and hepatic encephalopathy),
severe renal dysfunction (estimated GFR [eGFR] <
30 mL/min/1.73 m2), acute cerebrovascular accident,
acute infection, advanced cancer, a history of old myo-
cardial infarction or structural heart diseases including
cardiomyopathy or valvular disease, or a history of
coronary stenting or coronary bypass surgery.
Grouping
According to the results of CAG, the patients were
divided into a single-vascular-lesion group (group S,
91 cases), a dual-vascular-lesion group (group D, 67
cases), and a multiple-vascular-lesion group (group M,
37 cases).
Count of CAS lesions: Stenosis ≥50% in any one of the
three main coronary arteries (LAD, LCX, or RCA) was
considered a significant lesion. Stenosis ≥50% of the left
main stem was considered a dual-vascular lesion. Sten-
osis ≥50% of the intermediate branch was considered a
single vascular lesion. Stenosis of a branch was consid-
ered a main vascular lesion. The sum of the diseased
vessels with meaningful stenosis was then calculated.
Baseline information
In addition to the baseline data, all the patients under-
went electrocardiography (ECG) to calculate the left
ventricular ejection fraction (LVEF) before and after
admission (outpatient). The patients with STEMI and
NSTEMI in each ACS subgroup were then categorized
according to the Killip classification.
ECG evaluation
A total of 187 patients completed ECG, with 152 com-
pleted within 48 h of admission using the Philips IE 33
ultrasound system. Thirty-five patients underwent ECG
within 1 month of admission using the Philips HD 11
ultrasound system. LVEF was checked using M-mode
ultrasonography and obtained using Simpson’s principle.
Assessment of CAD severity
Assessment of CAD was performed according to the
modified Gensini score [11].
Killip classification
The Killip classification is a clinical classification of
acute myocardial infarction-induced heart failure, and its
classification standards were in accordance with the
diagnostic criteria of ACS defined by the ACC/AHA in
2014 [10].
Detection and grouping of serum CysC levels
A 4-mL sample of serum from each patient was sub-
jected to a turbidimetric immunoassay to measure the
concentration of serum CysC using was the Hitachi
7600-120 automatic biochemical analyzer; the kit was
provided by Kyokuto (Tokyo, Japan). The normal refer-
ence value of CysC is ≤1.0 mg/L. The serum CysC con-
centration for all patients was measured within 24 h
after admission.
CysC grouping: The CysC levels of all the hospitalized
patients (234 cases) were divided into four subgroups ac-
cording to the interquartile method: subgroup Q1, CysC
< 1.1 mg/L (45 cases); subgroup Q2, 1.1 mg/L ≤CysC <
1.2 mg/L (35 cases); subgroup Q3, 1.2 mg/L ≤CysC <
1.5 mg/L (88 cases); and subgroup Q4, CysC ≥ 1.5 mg/L
(66 cases).
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eGFR and grouping
The level of serum creatinine (Scr) was determined
using a Hitachi automatic biochemical analyzer, and
eGFR was calculated using the Cockcroft–Gault formula:
Ccr (mL/min) = [(140 - age) × body weight (kg) × (0.85
(female)]/(72 × Scr [mg/dL]).
The eGFR levels of all the hospitalized patients (234
cases) were divided into three subgroups according to
the degree of renal dysfunction: subgroup q1, moderate
to severe renal dysfunction (30 mL/min ≤ eGFR <
60 mL/min) (44 cases); subgroup q2, mild to moderate
renal dysfunction (60 mL/min ≤ eGFR < 90 mL/min) (94
cases); and subgroup q3, normal renal function (96
cases).
Statistical analysis
The quantitative data are expressed as mean ± standard
deviation. When homogeneity of variance existed among
the groups, a t test was used to compare count data;
otherwise, the t’ test was used. The CysC classification
data are described as median (interquartile range), and
the intergroup comparisons were made using the
Wilcoxon rank sum test. Qualitative data are described
as frequency (percentage), and the differences in CysC
and eGFR in different vascular lesion subgroups were
analyzed used the χ2 test. Correlations of CysC and
eGFR with the Gensini score were analyzed using Pear-
son’s correlation coefficient. The relationship of each
individual variable with ACS was then observed, and a
single logistic regression model was established. To
eliminate interference of confounding factors, a multi-
variate logistic regression model containing the main
effects was established, and the predictive values of the
variables with respect to the results were then analyzed.
A multivariate logistic prediction model was established,
with the inclusion criterion of P ≤ 0.05 and the exclusion
criterion of P > 0.05. When the outcome variables were
dichotomous, a nonconditional logistic regression model
was established; when the outcome variables were
ordered and categorical, an ordinal logistic regression
model was established. Bilateral levels were set for the P
values of all hypothetical tests, with the significance level
set at 5% and the homogeneity of variance level was set




Compared with the control group, the proportion of
male patients was significantly higher (P < 0.01), age was
lower (P < 0.05), and the low-density lipoprotein choles-
terol (LDL-C) level was higher (P < 0.01) in the STEMI
group. Compared with the control group, the proportion
of male patients was significantly higher (P < 0.01), the
percentage of patients with diabetes was higher (P <
0.05), and the LDL-C level was higher (P < 0.05) in the
NSTEMI group (Table 1).
The comparison of different variables among different
ACS subgroups (group S, D, and M) and the control
group showed that the proportion of male patients in
each ACS subgroup was higher than that of the control
group, and the comparison among different ACS sub-
groups showed the results as group M > group S > group
D (P < 0.05); the LDL-C level in each ACS subgroup was
higher than that of the control group, and the compari-
son among different ACS subgroups showed the results
as group D > group M > group S (P < 0.05); the CysC
levels in groups D and M were higher than that of the
control group, and the comparison among different ACS
subgroups showed the results as group M > group D >
group S (P < 0.05). Differences in age, proportion of
patients with hypertension, proportion of patients with
diabetes, LVEF, Killip grades, Scr level, and eGFR among
the groups were not statistically significant (P > 0.05,
Table 2).
Table 1 Baseline clinical baseline characteristic of all patients
STEMI group (n = 77) NSTEMI group (n = 35) UAP group (n = 83) Control group (n = 39)
Sex Male 165 (84.42%)** 29 (82.86%)** 57 (68.67%) 20 (51.28%)
Female 412 (15.58%) 6 (17.14%) 26 (31.33%) 19 (48.72%)
Age 59.19 ± 11.76* 67.14 ± 10.74 64.12 ± 10.36 64.59 ± 8.14
Hypertension 42 (54.55%) 25 (71.43%) 56 (67.47%) 23 (58.97%)
Diabetes 20 (25.97%) 14 (40.00%)* 25 (30.12%) 6 (15.38%)
LDL-C 3.11 ± 1.02** 3.07 ± 0.91* 2.65 ± 0.98 2.60 ± 0.77
Serum creatinine 74.78 ± 19.63 82.05 ± 24.91 75.55 ± 18.82 75.87 ± 19.73
Cys C 1.34 ± 0.48 1.46 ± 0.58 1.26 ± 0.27 1.30 ± 0.35
eGFR 99.47 ± 35.44 84.72 ± 35.42 83.03 ± 25.02 81.44 ± 23.95
Note: compared with control group
*P < 0.05
**P < 0.01
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Relationships between different variables and vascular
lesions
Using a univariate logistic regression model while not
controlling other factors, each variable was evaluated
regarding correlation with vascular lesions. The results
showed that the gender composition (male) and LDL-C
and CysC levels were positively correlated with vascular
lesions (P < 0.05), but the correlations of eGFR and other
variables did not reach statistical significance (P > 0.05)
(Table 3).
Using a multivariate logistic regression model while
controlling other factors, each variable was analyzed
regarding correlation with vascular lesions. The results
showed that CysC level, gender composition (male),
LDL-C level, and hypertension were positively correlated
with vascular lesions (P < 0.05). For the CysC level, the
odds ratio was 2.09, indicating that when CysC was
increased by 1 mg/L, the risk of an additional vascular
lesion increased by 2.09 times. Because the P value of
eGFR in the univariate regression analysis was too high
(0.937), it was not included in the multivariate statistical
regression model (Table 4).
Linear relation of CysC and eGFR with Scr values
CysC and Scr levels were measured in 234 patients
after they were hospitalized, and eGFR values were
calculated. A positive correlation was detected be-
tween CysC and Scr values based on Pearson’s
correlation coefficient (r = 0.6158, P < 0.0001), and a
negative correlation was detected between eGFR and
CysC level (r = -0.5115, P < 0.0001) and between eGFR
and Scr level (r = -0.5545, P < 0.0001) (Fig. 1).
Relationships of CysC level and kidney function with
vascular lesions
By comparing the constitute ratio differences of different
CysC levels (four subgroups) and different eGFR levels
(three subgroups) in different vascular lesion groups, the
correlations of different CysC levels and kidney dysfunc-
tion with vascular lesions were determined. Among the
CysC subgroups, the constitute ratios in subgroup Q1
(low CysC concentration) were group S > group D >
group M and those in subgroup Q4 (high CysC concen-
tration) were group M > group D > group S; these differ-
ences were statistically significant (P < 0.05). Among the
different eGFR subgroups, the constitute ratios in sub-
group q1 (moderate to severe renal dysfunction) were
group M > group D > group S, those in subgroup q2
(mild to moderate renal dysfunction), and those in sub-
group q3 (normal renal function) were group S > group
D > group M, but the differences were not statistically
significant (P > 0.05) (Table 5).
Comparison of CysC medians
According to the CysC ranges and medians in different
vascular lesion subgroups, a box plot could be drawn
Table 2 Variable comparison among different lesion groups
Index Control (n = 39) S (n = 91) D (n = 67) M ( n = 37) P
Gender 0.0153
F 19 (48.72%) 20 (21.98%) 16 (23.88%) 8 (21.62%)
M 20 (51.28%) 71 (78.02%) 51 (76.12%) 29 (78.38%)
Age 63.59 ± 9.14 62.40 ± 10.56 61.67 ± 12.12 66.49 ± 10.70 0.1591
Hypertension 23 (58.97%) 53 (58.24%) 40 (59.70%) 30 (81.08%) 0.0670
LDL-C 2.60 ± 0.77 2.74 ± 1.07 3.10 ± 0.91 2.97 ± 1.03 0.0449
Diabetics 6 (15.38%) 27 (29.67%) 21 (31.34%) 11 (29.73%) 0.2608
LVEF - 59.16 ± 5.17a 60.60 ± 5.67b 58.05 ± 8.00 0.0644
Killip classification 0.1090
Grade I - 31 (77.50%)c 32 (86.49%)d 15 (68.18%)e
Grade II - 8 (20.00%)c 3 (8.11%)d 2 (9.09%)e
Grade III - 1 (2.50%)c 2 (5.41%)d 4 (18.18%)e
Grade IV - 0 (0.00%)c 0 (0.00%)d 1 (4.55%)e
Cys C 1.30 ± 0.35 1.27 ± 0.30 1.34 ± 0.44 1.51 ± 0.59 0.0296
Scr 75.87 ± 19.73 73.29 ± 14.82 77.87 ± 21.31 80.84 ± 29.00 0.2370
eGFR 81.44 ± 23.95 92.31 ± 31.02 90.05 ± 32.50 83.56 ± 34.39 0.2146
Note:
athe cases with valid LVEF data in group S were 88 cases
bthe cases with valid LVEF data in group D were 62 cases
cthe cases with valid Killip classification data in group S were 40 cases
dthe cases with valid Killip classification data in group D were 37 cases
ethe cases with valid Killip classification data in group M were 22 cases
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(Fig. 2a). As seen from the box plot, with an increase in
vascular lesions, the median CysC level showed an in-
creasing trend. The Spearman rank correlation coeffi-
cient between these two was 0.1576, which reached
statistical significance (P = 0.0278). Quantile regression
analysis showed that the median CysC level was in-
creased on average by 0.1 mg/L for each additional
vascular lesion (P = 0.513) (Fig. 2a).
Comparison of eGFR medians
According to the eGFR ranges and medians in different
vascular lesion subgroups, a box plot could be drawn
(Fig. 2b). As seen from the box plot, with an increase in
vascular lesions, the median eGFR showed a decreas-
ing trend. The Spearman rank correlation coefficient
between these two was -0.0993, which did not reach
statistical significance (P = 0.1671). Quantile regression
analysis showed that the median eGFR was decreased
on average by 2.0 for each additional vascular lesion
(P = 0.086) (Fig. 2b).
Correlation comparison of different vascular lesions and
severity
By comparing the differences in Gensini scores among
the different vascular lesion subgroups, the correlations
of vascular lesions with Gensini scores were determined.
Gensini scores showed differences among different sub-
groups, with group M > group D > group S, and the
differences were statistically significant (67.32 ± 40.04 vs.
43.78 ± 25.50 vs. 30.20 ± 22.92, P < 0.0001).
Correlations of different CysC levels with vascular lesion
severity
By comparing the differences of Gensini scores among
different CysC subgroups, the correlations of CysC levels
with Gensini scores were then determined. The
results showed that the Gensini scores showed differ-
ences among different CysC subgroups, subgroup
Q4 > subgroup Q 3 > subgroup Q2 > subgroup Q1, and
the differences were statistically significant (50.00 ±
37.37 vs. 42.67 ± 30.40 vs. 39.13 ± 22.58 vs. 30.24 ±
22.25 mg/L, P < 0.05).
Correlations of different renal functions with vascular
lesion severity
By comparing the differences of Gensini scores
among different eGFR subgroups, the correlations of
different renal functions with Gensini scores were
then determined. The results showed that the Gensini
scores showed differences among different eGFR sub-
groups, subgroup q3 > subgroup q1 > subgroup q2, but
the differences were not statistically significant (43.2
± 29.84 vs. 41.54 ± 35.65 vs. 40.91 ± 30.97 mL/min/
1.73 m2, P > 0.05).
Linear relationships of serum CysC level, eGFR, and
Gensini score
Pearson’s correlation coefficient was used to calculate
the paired linear relationships among CysC level, eGFR,
and Gensini score. CysC was negatively correlated with
eGFR (r = -0.5073, P < 0.0001) but positively correlated
with Gensini score (r = 0.1811, P < 0.05); eGFR and
Gensini score were positively correlated (r = 0.0738, P >
0.05) (Fig. 3).
Correlations of different Killip grades with vascular lesion
severity
By comparing the differences in Gensini scores among the
different Killip classification subgroups, the correlations of
Table 3 Univariate logistic regression analysis of different variables with vascular lesions
Factor Coefficient SD Statistic P OR (95%CI)
M 0.6362047 0.2794 2.28 0.0230 1.8893 (1.0927–3.2667)
Age 0.0080341 0.0108 0.75 0.4560 1.0081 (0.9870–1.0296)
Hypertension 0.4309775 0.2446 1.76 0.0780 1.5388 (0.9528–2.4851)
LDL-C 0.3062137 0.1254 2.44 0.0150 1.3583 (1.0623–1.7367)
Diabetics 0.3487115 0.2616 1.33 0.1830 1.4172 (0.8487–2.3666)
Cys C 0.7297879 0.3015 2.42 0.0150 2.0746 (1.1490–3.7459)
Scr 0.0103784 0.0061 1.70 0.0890 1.0104 (0.9984–1.0226)
eGFR 0.0002985 0.0038 0.08 0.9370 1.0003 (0.9929–1.0078)
Table 4 Multivariate logistic regression analysis of different
variables with vascular lesions
Factor Coefficient SD Statistic P OR (95%CI)
Cys C 0.736095 0.3095 2.38 0.0170 2.0878 (1.1382–
3.8295)
Male 0.776684 0.2928 2.65 0.0080 2.1743 (1.2250–
3.85920)
LDL-C 0.329243 0.1270 2.59 0.0100 1.3899 (1.08360–
1.7828)
Hypertension 0.514262 0.2565 2.00 0.0450 1.6724 (1.0115–
2.7650)
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Killip grades with Gensini scores were then determined.
Gensini scores showed differences among different Killip
classification subgroups, with Killip grade IV (one case) >
Killip grade II > Killip grade III > Killip grade I, but the dif-
ferences were not statistically significant (168.00 ± 0.00 vs.
67.15 ± 39.32 vs. 51.57 ± 16.78 vs. 46.36 ± 26.53, P > 0.05).
Discussion
The purpose of this study was to investigate the correla-
tions of serum CysC level and eGFR with vascular
lesions and their severity in patients with ACS. In recent
years, some scholars suggested that inflammation and
immune responses were the intermediary and key
factors of cardiovascular remodeling and onset [12].
Cardiovascular events such as acute myocardial infarc-
tion are related to the inflammatory activities of lesions
and matrix remodeling induced by plaque rupture.
Optical coherence tomography is a feasible and safe im-
aging modality for patients with CAD and allows identi-
fication of the various microstructures of the
atherosclerotic plaque such as plaque rupture, thin-cap
fibroatheroma, lipid core, and intracoronary thrombus
[13]. Many studies observed that the weakening process
of fibrous caps mainly resulted from extracellular matrix
degradation, which was caused by activated proteases
such as matrix metalloproteinases and serine proteases
released by the activated macrophages and smooth
muscle cells in the plaques [14, 15]. Recently, two cyst-
eine proteases that could promote the dissolving of elas-
tic tissues, cathepsin S and cathepsin K, were found to
be overexpressed in atherosclerotic lesions [16]. The
main functions of serum CysC are to inhibit the activity
of endogenous cysteine proteases, to regulate the intra-
cellular metabolism of proteins [17], and to play the role
of inflammatory mediators through activating neutro-
phils [18]; its mechanisms are involved in inhibiting
inflammatory factors, confronting plasminogens, regulat-
ing the activity of pre-hormones, and regulating protein-
ases inside and outside cells [19–21]. Studies have
shown that the serum CysC level was related to the
severity of ACS [22]. Tebaldi [23] found that a re-
duced CrCl value (45 mL/min) was independently as-
sociated with a significantly lower incidence of
positive FFR (0.80 or less). Regarding correlations be-
tween coronary vascular lesions and the severity of
coronary vascular diseases, Corpus [24] found that
the incidence of major adverse cardiac events such as
death, repeated myocardial infarction, or repeated
revascularization in patients with acute myocardial
infarction plus multiple vascular lesions during the 1-
year follow-up period was significantly higher than in
patients with a single vascular lesion. Their results
suggested that the ACS patients with multiple
Fig. 1 Scatterplots showed linear relationships between serum cystatin C, eGFR and Scr
Table 5 Comparison of constitute ratio differences of different
Cys C subgroups and different eGFR subgroups in different
vascular lesion groups
Index S D M Statistic P
Cys C Q1 23 (25.27%) 10 (14.93%) 4 (10.81%) Z = 7.25 0.0267
Q2 12 (13.19%) 13 (19.40%) 5 (13.51%)
Q3 35 (38.46%) 26 (38.81%) 10 (27.03%)
Q4 21 (23.08%) 18 (26.87%) 18 (48.65%)
eGFR q1 13 (14.29%) 12 (17.91%) 10 (29.73%) Z = 2.90 0.2342
q2 36 (39.56%) 26 (38.81%) 13 (35.14%)
q3 42 (46.15%) 29 (43.28%) 13 (35.14%)
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vascular lesions had more severe disease and a worse
prognosis.
The analysis of correlations between CysC level and
vascular lesions in the ACS patients showed the CysC
levels in group D and M were higher than those in the
control group, and the comparison among different ACS
subgroups showed group M > group D > group S (group
M 1.51 ± 0.59 mg/L vs. group D 1.34 ± 0.44 mg/L vs.
group S 1.27 ± 0.30 mg/L vs. control group 1.30 ±
0.35 mg/L, P = 0.0296). The single-factor regression
analysis of the vascular lesions in these ACS patients
suggested that the CysC level was positively corre-
lated with the vascular lesions (P = 0.0150), and the
multifactor regression analysis showed the same result
(P = 0.017); among different CysC subgroups, the con-
stitute ratios in the lower-quartile groups were group
S > group D > group M, and those in the high-quartile
groups were group M > group D > group S, and the
differences were statistically significant (P < 0.0267). It
could be seen from the box plot (Fig. 2a) that with
increasing vascular lesions, the median CysC level
also showed an increasing trend. The Spearman rank
correlation coefficient of these two was 0.1576 (P =
0.0278).
The analysis of correlations between CysC level and
vascular lesion severity in the ACS patients showed that
the Gensini scores exhibited differences among different
CysC subgroups, with subgroup Q4 (high-quartile group,
50.00 ± 37.37 mg/L) > subgroup Q3 (42.67 ± 30.40 mg/L) >
subgroup Q2 (39.13 ± 22.58 mg/L) > subgroup Q (lower-
quartile group) 30.24 ± 22.25 mg/L (P = 0.0286). Using the
scatterplot matrix of CysC, eGFR, and Gensini scores,
Pearson’s correlation coefficient calculation showed
that CysC was positively correlated with the Gensini
score (r = 0.1811, P < 0.05).
The results of this study suggested that CysC level
was positively correlated with the vascular lesions and
their severity in these ACS patients, and the differ-
ences were statistically significant, consistent with the
results of Jernberg [22]. Meanwhile, the comparison
between the vascular lesions and Gensini scores in
the ACS patients showed that group M (67.32 ±
40.04 mg/L) > group D (43.78 ± 25.50 mg/L) > group S
(30.20 ± 22.92 mg/L) (P < 0.0001), fully consistent with
the results of Corpus [24].
The inconsistent results regarding CysC mainly derives
from the fact that CysC is just one member of the cyst-
eine protease inhibitors, and CysC and its fragment can
regulate inflammatory processes and participate in the
pathological physiological process of atherosclerotic
plaque formation. CysC may inhibit the activity of
cathepsin S and K, reduce degradation of blood vessels
and vascular remodeling, and postpone the occurrence
and development of atherosclerosis. Patients with in-
creased CysC levels may have higher cardiac mortality,
and the mortality of patients with higher CysC levels
Fig. 2 a Correlation of Cys C median with different vascular disease variables by box-plot; Note: Abscissa 1 represented group S, 2 represented
group D, 3 represented group M, the ordinate represented the Cys C value, and the transverse lines in the blocks represented the
medians. b Correlation of eGFR median with different vascular disease variables by box-plot. Note: Abscissa 1 represented group S, 2 represented
group D, 3 represented group M, the ordinate represented the eGFR value, and the transverse lines in the blocks represented the medians
Fig. 3 Scatterplot matrix among Cys C, eGFR, and Gensini score in
patients with ACS. The pair Pearson correlation coefficients among
the above three indexes
Zhang et al. BMC Cardiovascular Disorders  (2017) 17:47 Page 7 of 9
was 3.87-fold higher than that in patients with lower
CysC levels. Sai E et al. [25] found that increased CysC
levels can be a predictive factor of recurrence of cardio-
vascular events, which may be derived from the fact that
CysC contributes to the pathological physiological
process of atherosclerosis and inflammation. However,
there are still multiple contradictions with respect to the
relationship between CysC and CHD. For these contra-
dictions, Noto et al. [26] believed that the difference is
mainly caused by a negative acute-phase reaction during
acute myocardial infarction. The case of a patient with
acute myocardial infarction who had normal expression
levels of CysC after 7 days in the hospital also supports
this hypothesis. However, another hypothesis indicated
that the expression of CysC is reduced before acute car-
diovascular events, which further activates inflammatory
factors and cell factors and induces a lower level of
CysC. One study showed that transforming growth fac-
tor β1 (TGF-β1) is an important factor inducing CysC
[27]; serum TGF-β1 levels are significantly reduced in
atherosclerosis, and increased TGF-β1 can inhibit the
process of lesion formation. CysC levels are near normal
in the recovery phase, and may even be increased, which
is also caused by regulation of inflammatory and cell fac-
tors, body compensatory mechanisms, and the gradual
repair and conserved result of inflammatory patches.
Luc et al. [28] found that ischemic events may be caused
by a relative shortage of proteinase inhibitors (such as
CysC). Although the inflammatory process increased the
expression of CysC, CysC is still not enough than
increased protease in inflammatory atheromatous
plaques.
Collectively, many clinical studies have shown that
CysC is related to CHD. Patients with ACS with vascular
lesions should be further studied owing to the limited
number of samples in this study. Simultaneously, deter-
mining whether CysC can be used as a potential
biomarker for prognostic evaluation and prediction of
major adverse cardiac events and has potential guiding
significance and value for revascularization will be the
next research direction.
Conclusions
Serum CysC levels might reflect the severity of vascular
lesions in patients with ACS, and high CysC levels had a
predictive value regarding the severity of vascular lesions
in ACS.
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